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Abstract 
The kidney plays a major physiological role in glucose homeostasis but also contributes to 
the pathophysiology of type 2 diabetes (T2D), mediated by renal sodium glucose 
cotransporters (SGLTs). This recognition led to development of SGLT2 inhibitors that inhibit 
proximal renal tubular renal glucose and sodium reabsorption. The glucoretic and natriuretic 
effect of SGLT2 inhibitors is associated with reductions in HbA1c levels, body weight, 
systolic blood pressure and triglycerides. 
Major vascular complications of T2D include cardiovascular disease and chronic kidney 
disease (CKD). Results from several cardiovascular outcome trials (CVOTs) with these drugs 
have highlighted benefits in reducing major adverse cardiovascular events by 11%, reducing 
the risk of cardiovascular death or hospitalisation for heart failure (HF) by 23% and reducing 
risk of progression of renal disease by 45%. Their cardiorenal benefits are apparent across a 
range of eGFRs (within CKD1-3 groups) and the presence or absence of ischaemic heart 
disease, HF or T2D. In patients with HF with reduced ejection fraction (HFrEF), similar risk 
reductions in cardiovascular death and HF events are also seen; results from studies in 
patients with HF with preserved ejection fraction (HFpEF) are awaited. Cardiorenal benefits 
have been recently reported in patients with CKD, regardless of the presence or absence of 
T2D.  
Indications for use of SGLT2 inhibitors has extended beyond glucose-lowering to a central 
role in cardiorenal protection. This review will first explore the mechanisms by which 
glycaemic control, weight loss and cardiovascular risk factors are modulated therapeutically 
with SGLT2 inhibitors. Subsequently we outline putative mechanisms underpinning the 
cardiorenal benefits seen, including in HF and CKD, in the context of completed and ongoing 
clinical studies. Treatment strategies with SGLT2 inhibitors in individuals with CKD or HF, 
with and/or without T2D are increasingly appealing. Combination therapy with 
complementary therapeutic agents is also explored. 
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Introduction 
A. The role of the kidney in glucose homeostasis and renal glucose transport 
Glucose homeostasis the various roles of the kidney include excretion of metabolic waste 
products, maintenance of intravascular volume and serum osmolality, regulation of blood 
pressure, acid-base and electrolyte balance through filtration, secretion and selective 
reabsorption of key ions. The kidney also has a major physiological role in regulating glucose 
homeostasis constantly supplying glucose to the brain despite diurnal changes in nutrient 
availability. The involvement of the kidney in gluconeogenesis was first described in 1938 in 
rabbits, where the amount of glucose required to maintain euglycemia was considerably 
higher after hepatectomy plus nephrectomy vs. hepatectomy only [1]. 
Maintenance of whole-body glucose homeostasis involves several complementary inter-
organ physiological processes, including glucose absorption (gastrointestinal tract), 
glycogenolysis (liver), gluconeogenesis (liver and kidneys), glucose reabsorption and 
excretion (kidneys). Renal glucose utilisation, occurring predominantly in the renal medulla, 
constitutes ~10% of whole-body glucose uptake to satisfy the kidneys’ energy requirements, 
while renal glucose release into the systemic circulation, via glycogenolysis and 
gluconeogenesis, is limited to the renal cortex. The kidney contributes up to 20% of glucose 
released into the systemic circulation under post-absorptive conditions, increasing up to 60% 
post-prandially[2]. These distinct metabolic roles reflect differences in the anatomical 
distribution of various enzymes along the nephron. Evidence suggests that in patients with 
T2D, renal gluconeogenesis is increased (vs. healthy controls) in both the post-prandial and 
post-absorptive states [3]. 
Glucose filtration and reabsorption The kidneys also contribute to glucose homeostasis by 
filtering and reabsorbing glucose. The total amount of glucose stored in the body is ~450 g, 
with ~170g of glucose produced daily (via gluconeogenesis and glycogenolysis). With 
glomerular filtration of 180 litres/day, the kidney filters 162 g of glucose (180l x 90 mg/dl; 
90mg/dl~5.0 mmol/l) daily. The amount of glucose filtered increases linearly with increasing 
plasma glucose concentration; glucose is almost entirely reabsorbed in the proximal renal 
tubules. The renal threshold for reabsorption is a plasma glucose concentration ~8.3 mmol/l, 
above which glucose starts to appear in the urine. Once plasma glucose concentration is 
>13.3 mmol/l, the maximum capacity for glucose reabsorption is exceeded (tubular 
maximum for glucose, TmG), and thus beyond this threshold, the degree of glucosuria 
increases in a linear fashion with increasing plasma glucose concentrations (Figure 1). 
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Glucose transport Glucose transport across cell membranes is dependent on two specialised 
carrier protein families: the GLUTs (facilitated glucose transporters) and the SGLTs (sodium 
coupled glucose cotransporters). GLUTs are responsible for passive transport across cell 
membranes to equilibrate the transmembrane concentration while SGLTs are involved in 
active glucose transport across a concentration gradient. There are two predominant isoforms 
of SGLTs: SGLT1 and SGLT2. SGLT1 is located in the small intestine (in the luminal brush 
border of the enterocyte) and in segment 3 of the proximal tubule, with specificity for glucose 
and galactose as a high affinity (Km=0.4mM), low capacity glucose carrier. SGLT2 is found 
in the renal proximal tubules (segments 1 and 2), with specificity for glucose as a low affinity 
(Km=2mM), high capacity glucose carrier. Thus, under normoglycaemic conditions, SGLT2, 
expressed in the early proximal tubule, accounts for ~90% of glucose reabsorption with the 
remainder by SGLT1 in segment 3 of the proximal tubule (Figure 2).  
Renal glucose transport in T2D Evidence from studies conducted in human renal tubular 
cells suggest SGLT2 and GLUT2 expression are upregulated in T2D, leading to an increased 
maximal capacity for glucose reabsorption (TmG) and a higher threshold for glycosuria and 
consequently increased glucose reabsorption [4]. Increased renal glucose reabsorption is a 
well-recognised pathophysiological defect of T2D [5].  
 
B. SGLT2 inhibitors  
SGLT1/2 receptor specificity The appreciation of the role of the kidney in regulating glucose 
homeostasis led to the development of new types of glucose-lowering drugs targeting this 
metabolic pathway. The original observations that augmenting renal glucose excretion could 
lead to improved glycaemic control came from animal studies using phlorizin, a naturally 
occurring molecule, that inhibits both SGLT1 and SGLT2 and subsequently several SGLT2 
and later dual SGLT1/2 inhibitors were developed. SGLT2 inhibitors in clinical use in 
Europe are dapagliflozin, canagliflozin, empagliflozin and ertugliflozin while sotagliflozin, 
the only dual SGLT1/2 inhibitor, is approved only for type 1 diabetes (T1D).  
The differing SGLT2 inhibitors have a range of relative specificities to the different SGLT 
receptors which may contribute to subtle differences in their clinical profiles. Highest 
selectivity for SGLT2 receptors is observed with empagliflozin (SGLT2:SGLT1 
specificity~2,500), with other agents intermediate in SGLT2 receptor specificity 
(dapagliflozin,1200; canagliflozin, 200) with sotagliflozin the least selective (~20).  
Despite our understanding that SGLT2 usually contributes to ~90% of glucose reabsorption 
in a healthy adult, pharmacological inhibition with an SGLT2 inhibitor only results in about 
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60-80 grams of urinary glucose excretion (~50-60% of filtered glucose load). With increased 
glucose load to the late proximal tubule, SGLT2 inhibition causes a compensatory increase in 
SGLT1-mediated glucose reabsorption to limit glucosuria and potential hypoglycaemia.[6] 
Additionally, inhibition of intestinal SGLT1-mediated glucose uptake may have further 
therapeutic benefit. This premise is supported by findings from studies in individuals who 
carry a haplotype of functionally damaging missense mutations in SGLT1, which due to 
reduced intestinal glucose uptake, have improved glucose tolerance and lower odds of 
impaired glucose tolerance [7]. The estimated 25-year effect of this reduction in glucose 
tolerance was concomitant reductions in prevalent obesity, incident diabetes, heart failure 
(HF) and death [7].  
Metabolic effects Sodium–glucose co-transporter 2 (SGLT2) inhibitors were introduced as a 
treatment for T2D but by virtue of the associated urinary excretion of glucose (and thus 
caloric loss), and urinary excretion of sodium, their use is associated with reductions in 
HbA1c levels, body weight and systolic blood pressure.  
Glycaemic effects All SGLT2 inhibitors show similar reductions in HbA1c when studied as 
monotherapy in drug-naive patients[8, 9], in combination with other oral agents[10-13] or 
insulin[14]. Although the short-term reduction in HbA1c with SGLT2 inhibitors is 
comparable to that achieved with sulphonylureas and DPP-IV inhibitors (0.7-1%), the 
durability of the glycaemic benefit appears to be better with SGLT2 inhibitors compared to 
these other drug classes [15, 16]  
Factors predicting glycaemic response A meta-analysis of randomised controlled studies, 
confirms that the magnitude of HbA1c reduction correlates with the baseline HbA1c, 
irrespective of the class or mode of action of glucose-lowering therapy, such that patients 
with higher HbA1c achieve greater reductions in than individuals with lower HbA1c [17]. 
However, this finding is particularly pertinent considering the efficacy of SGLT2 inhibitors, 
where with progressively higher baseline HbA1c, their glucose lowering effect not only 
increases but indeed exceeds that of other glucose-lowering therapies. Mechanistically, this is 
explained by significantly higher amounts of glucose filtered whose reabsorption can then be 
targeted by SGLT2 inhibitor therapy as the plasma glucose concentration and HbA1c 
progressively increases. Considering that their primary effect is mediated by inhibiting renal 
glucose absorption, provided that renal function (and thus glomerular filtration) is relatively 
preserved, these agents effect similar improvements in glycaemic control in newly diagnosed 
or longer duration T2D, irrespective of their degree of insulin sensitivity or residual insulin 
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secretion [18]. Renal impairment, (and thus impairment in glucose filtration), is associated 
with reduced efficacy of SGLT2 inhibitors in glycaemic reduction.  
Mechanisms of glucose lowering There are two mechanisms by which SGLT2 inhibitors 
improve glycaemic control. First, by their significant effects on modulating renal glucose 
excretion: reducing the maximal capacity for glucose reabsorption (TmG) and the threshold 
for glycosuria, promoting glycosuria of 60-80 grams/day[19]. Secondly, by amelioration of 
glucotoxicity (achieved through the reduction in plasma glucose concentration secondary to 
glycosuria) leading to greater insulin sensitivity in peripheral tissues (adipose tissue and 
skeletal muscle) [20] and enhancement of beta cell function, with improvements in the first 
and second phase of insulin secretion [21, 22]. These favourable metabolic changes are 
partially offset by an increase in endogenous glucose production, possibly the result of an 
increase in plasma glucagon concentrations. As their mechanism of action is independent of 
insulin secretion their use is associated with a low incidence of hypoglycaemia and therefore, 
they may be added to any background glucose-lowering treatment regimen. They may cause 
hypoglycaemia when used in combination with a sulphonyurea or insulin therapy. 
Weight loss The weight loss associated with SGLT inhibitors is typically around 2-3 kg after 
6 months’ treatment, the magnitude of which has been the subject of several meta-analyses 
[23]. Arguably, the weight loss associated with 300 mg canagliflozin is marginally greater 
than that of most other SGLT2 inhibitors[24]. The changes in body composition associated 
with this weight loss have been quantified and there is a reduction in total fat mass, visceral 
and subcutaneous adipose tissue [25]. The anticipated weight loss from SGLT2 inhibitor 
therapy has been calculated based on the known urinary glucose excretion of ~60–80g per 
day, which amounts to a caloric loss of 240–320 calories per day (glucose~4 kcal/g). 
Considering 3,500 calories is equivalent to 1lb of fat (0.45kg) the observed magnitude of 
weight loss is significantly less than anticipated if one looks at the longer-term weight loss 
(e.g. after 6 months). Based on results of studies in animals and humans treated with SGLT2 
inhibitors, it has been suggested that compensatory hyperphagia explains the attenuation of 
weight loss [26] and Hall et al, has modelled this to determine that for every kilogram of 
weight loss results in a proportional increase in appetite resulting in eating above baseline by 
approximately 100 kcal/day [27]. This concept of compensatory hyperphagia with SGLT2 
inhibitor therapy provides the rationale for the co-administration of an SGLT2 inhibitor with 
a GLP-1 receptor agonist to attenuate the central hyperphagic drive and ideally achieve 
additive, even synergistic, weight loss. Mechanistic explanations for weight loss associated 
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with SGLT2 inhibitors, with or without GLP1 receptor agonists have been discussed 
narratively [28]. 
Mechanisms of weight loss The mechanisms for weight loss is predominantly through urinary 
glucose (and associated caloric loss), natriuresis and aquaresis but there are other additional 
mechanisms. Reproducible changes in substrate utilisation such that fuel use switches from 
glucose oxidation to increased lipolysis, fat oxidation and formation of ketone bodies. 
Furthermore, in patients treated with SGLT2 inhibitors and sulphonylureas and/or insulin, the 
reduction in their dosage may also contribute to favourable weight change. 
Blood pressure reduction There are consistent sustained reductions in systolic (~5mmHg) 
and diastolic (~2mmHg) blood pressure with SGLT2 inhibitors, similar across all members of 
the class. With coupling of glucose and sodium reabsorption in the proximal tubule, SGLT2 
inhibition leads to a osmotic diuresis and mild natriuresis and a corresponding contraction in 
extracellular fluid and plasma volume [29]. These blood pressure lowering effects may 
extend to individuals without T2D[30]. 
Almost certainly it is a multi-factorial combination of mechanisms that contribute to the 
pathophysiology of CVD and CKD in T2D including the metabolic and haemodynamic 
abnormalities described above, together with other mechanisms such as lipotoxicity and 
oxidative stress; it is likely that their improvement/reversal explains the clinical benefits of 
SGLT2 inhibitors. 
 
C. Effects of SGLT2 inhibitors on the cardiovascular system  
T2D is a major cardiovascular risk factor, conferring a two-to three-fold excess risk of 
coronary artery disease including angina, myocardial infarction, stroke and HF, in patients 
with and without established cardiovascular disease [31, 32]. There has been much focus on 
understanding atherosclerotic complications (atherosclerotic CVD, ASCVD), with the 
relationship between T2D and HF less well understood. 
 
Effects on cardiovascular outcomes  
These initial studies described below, mandated by the FDA, aimed to demonstrate that 
SGLT2 inhibitors could be used in patients with T2D without causing an increase in major 
adverse cardiovascular events (MACE). The subsequent results of several of these key 
CVOTs have consistently reassured the medical community about the safety of SGLT2 
inhibitors and the associated reduction in cardiovascular events in patients with established 
CVD or at high risk of CV events. The discovery of their beneficial role in HF was somewhat 
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serendipitous [33]. Recent guidelines, updated to reflect these overwhelmingly positive 
results, recommend these drugs in patients either with T2D and CVD or at very high/high 
CV risk to reduce CV events and to reduce the risk of death [34]. 
EMPA-REG cardiovascular outcome study The EMPA-REG cardiovascular outcome trial 
(CVOT) assessed the effect of empagliflozin (10 mg or 25 mg once daily), compared with 
placebo, both added to standard of care comprising glucose-lowering agents and 
cardiovascular (CV) drugs (including anti-hypertensive and lipid-lowering agents) in 7,020 
patients over a median of 3.1 years. The clinical population was a high-risk clinical group 
with almost all having pre-existing CVD (~99%). The composite primary endpoint was a 3-
point MACE (defined as time to first occurrence of CV death, non-fatal heart attack or non-
fatal stroke). Empagliflozin significantly reduced the occurrence of the 3-point MACE by 14 
percent versus placebo. Risk of CV and all-cause mortality was reduced by 38 and 32 percent 
respectively, with no significant difference in the risk of non-fatal heart attack or non-fatal 
stroke. The benefits were observed with almost immediate effect following the initiation of 
empagliflozin treatment [35]. Subsequent trials with other SGLT2 inhibitors confirmed these 
observations across a broader range of patients with and without established vascular disease. 
CANVAS cardiovascular outcome study The Canagliflozin Cardiovascular Assessment Study 
(CANVAS) CVOT assessed the effect of canagliflozin (100mg or 300mg), compared with 
placebo, both added to standard of care in 10,142 patients with T2D and high cardiovascular 
risk (65.6% had a history of cardiovascular disease) [36]. Patients were followed for a mean 
of 188.2 weeks. The composite primary endpoint was a 3-point MACE and canagliflozin 
significantly reduced the risk of the composite measure by 14 percent versus placebo. 
However, as in EMPA-REG the individual effects on CV death, non-fatal MI or non-fatal 
stroke did not reach statistical significance. Canagliflozin also caused a 33% reduction for 
HF. Adverse reactions included an increased risk of amputations, primarily at the level of the 
toe or metatarsal.  
DECLARE-TIMI The Dapagliflozin to assess Cardiovascular Events trial was the largest 
study to assess the effect of an SGLT2 inhibitor, namely dapagliflozin, in 17,160 patients 
with established CVD (40.6%) or with multiple risk factors for atherosclerotic CVD (59.4%) 
(i.e. primary and secondary prevention) for a median of 4.2 years[37]. Dapagliflozin 
demonstrated non-inferiority for MACE (hazard ratio, HR 0.93; 95% CI 0.84,1.03) but 
resulted in a lower rate of a composite of CV death or hospitalisation for HF (HR 0.83; 95% 
CI 0.73,0.95), due to a lower rate hospitalisation for HF, regardless of previous ASCVD or 
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HF (HR 0.73; 95% CI 0.61, 0.88). These studies have led to approval of SGLT2 inhibitors for 
the indication of a reduction in risk of CV events and death in patients with T2D.  
Meta-analyses of SGLT2 CVOTs Several meta-analyses have recently been published on 
SGLT2 inhibitors for primary and secondary prevention of cardiovascular outcomes in T2D 
with an attempt to reconcile what patient characteristics (e.g. presence/absence of 
atherosclerotic cardiovascular disease (ASCVD), history of HF or baseline renal function) 
will derive cardiorenal protection [38, 39]. Incorporating data from 34,322 patients in EMPA-
REG OUTCOME, CANVAS and DECLARE-TIMI 58, the clinical benefits of SGLT2 
inhibitors are in reducing the risk of a 3-point MACE (MI, stroke or cardiovascular death) 
only in those with established CVD (HR 0.86; 95% CI 0.80,0.93) and not in those with 
multiple risk factors (HR 1.00; 95% CI 0.87, 1.16) (Figure 3).  
Cardiovascular safety of the dual SGLT1/SGLT2 inhibitor sotagliflozin is being tested in the 
SCORED trial in patients with T2D, moderate renal impairment and high cardiovascular risk 
(NCT 03315143). 
 
Effects on HF 
HF is a major public health issue affecting up to 63 million people worldwide [40], with 1 in 
5 people expected to develop HF during their lifetime [41]. T2D is a common co-morbidity 
in HF patients: not only is T2D a major risk factor for the development of HF but it also 
represents a major adverse prognostic factor in those with established HF [42, 43]. Chronic 
HF is the leading cause of hospitalisation in patients over 65 years old [44], with those 
hospitalised having a 10%, 30-day and 50%, 1-year mortality.  
Patients with T2D may develop two distinct phenotypes of HF according to their ejection 
fraction.  
HFrEF Many develop HF with a reduced ejection fraction (EF<40%, HFrEF), typically 
characterised by a loss and stretch of cardiac myocytes, left ventricular enlargement and 
increased serum natriuretic peptides; these patients respond to treatment with neurohormonal 
antagonists (inhibitors of the renin-angiotensin system including ACE-inhibitors, angiotensin 
receptor blockers, angiotensin receptor neprilysin inhibitors, beta-blockers and 
mineralocorticoid receptor antagonists, MRA).  
HFpEF Others will develop HF with preserved ejection fraction (EF>50%; HFpEF) 
characterised by systemic and adipose tissue inflammation, microvascular dysfunction and 
myocardial fibrosis. In contrast, such patients do not have significantly increased LV size or 
concentrations of serum natriuretic peptides and show little/no response to neurohormonal 
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antagonists [45]. There is an additional intermediate phenotype with midrange EF 40-50%. 
Observational studies highlight a shifting pattern of the epidemic with the prevalence of 
HFpEF increasing relative to HFrEF[46], likely to constitute ~65% of the total HF burden. 
This is consistent with the increasing prevalence of comorbidities such as T2D, obesity, 
hypertension etc. that drive disease progression in HFpEF. Considering this rising prevalence 
there is a need for recognition of individuals at risk and identifying the presence of preclinical 
cardiac structural/functional HF may help to prevent progression and improve clinical 
outcomes.  
Effects of glucose-lowering therapies Metformin has been associated with positive effects in 
HF, certain DPP-4 inhibitors (saxagliptin) and thiazolidinediones are not recommended and 
the evidence for GLP-1 agonists is inconclusive while results from four large-scale clinical 
trials of >36,000 patients with T2D suggest that SGLT2 inhibitors have a role in the 
prevention of HF [39]. The three main SGLT2 inhibitors (empagliflozin, canagliflozin and 
dapagliflozin) lowered the risk of hospitalisation for HF by ~25-35%, with the benefits 
almost immediately apparent on initiation of treatment and persisted throughout the follow up 
period of 2-5 years. Only 10-15% of these trial patients had documented HF around the time 
of randomisation. Significantly a similar benefit was observed in patients with and without 
atherosclerotic cardiovascular disease and with and without a history of HF[39]. From meta-
analyses of SGLT2 inhibitors and HF from the various CVOTs, the risk reduction in 
hospitalisation for HF was evident regardless of presence of ASCVD or HF at baseline [39] 
(Figure 3). Significantly, analysis of data from DECLARE and CANVAS suggested the risk 
of hospitalisation for HF was reduced in patients with and without HFrEF suggesting 
potential benefit in patients with HFpEF in whom no treatment has been shown to be of 
benefit[47, 48].  
DAPA-HF Recently a large randomised, controlled study (DAPA-HF) of dapagliflozin 10mg 
once daily was undertaken in 4,744 patients, mean age 66 years, with symptomatic HF and 
reduced ejection fraction (HFrEF); mean baseline EF was ~31%. The patients were already 
receiving excellent background HF therapy with neurohormonal antagonists (>90% renin-
angiotensin system inhibitors, >70% MRAs). Over a median follow up of 18.2 months 
dapagliflozin reduced the risk of the primary composite end-point of cardiovascular death 
and HF events (hospitalisation or an ambulatory visit for intravenous diuretic therapy) by 
26% [49]. CV death was significantly reduced by 18% and all-cause mortality by 17%. 
Significantly only 42% had T2D and >40% did not have underlying ischaemic heart disease. 
The magnitude of clinical benefit on the primary outcome was observed irrespective of age 
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and was similar in patients with or without T2D and with or without ischaemic heart disease. 
The number needed to treat (over 18 months) was only 21, supporting a large absolute risk 
reduction. 
EMPA-RESPONSE-AHF To test the hypothesis that SGLT2 inhibitors may be effective in 
patients with acute decompensated HF, a pilot study with empagliflozin was performed. In 
this randomised, placebo-controlled, double-blind, parallel group, multicentre study, 80 acute 
HF patients, with and without diabetes, were randomised to receive either empagliflozin 
10 mg/day or placebo for 30 days. Although empagliflozin had no effect on change in VAS 
dyspnoea, diuretic response, serum NT-proBNP and length of hospital stay it was deemed to 
be safe, increased urinary output and reduced a combined endpoint of in-hospital worsening 
HF, rehospitalization for HF or death at 60 days compared with placebo [4 (10%) vs. 13 
(33%); P=0.014] [50]. 
The implications of the findings of these studies are that SGLT2 inhibitors appear to reduce 
the risk of hospitalisation for HF in patients both without a pre-existing diagnosis of HF and 
in those with established HF; applicable for non-diabetic patients and those with T2D. In 
May 2020, dapagliflozin was the first SGLT2 inhibitor to be approved for the use of HF with 
reduced ejection fraction by the Federal Drug Administration (FDA).  
Current HF studies There are several ongoing studies of SGLT2 inhibition in patient cohorts 
with different phenotypes of HF (Figure 4). The EMPEROR-Reduced trial is examining the 
effect of empagliflozin in patients, with and without T2D, with more advanced HF (lower LV 
ejection fraction and higher serum concentrations of natriuretic peptides). EMPEROR-
Preserved with empagliflozin and DELIVER with dapagliflozin will evaluate the effects of 
SGLT2 inhibition in patients with an established diagnosis of HFpEF. If these studies 
highlight a beneficial impact on HF events in HFpEF this will substantially broaden the 
clinical indications of these drugs.  
 
Effects on atrial fibrillation In a recent analysis of DECLARE, dapagliflozin was shown to 
decrease the incidence of reported episodes of atrial fibrillation/atrial flutter (AF/AFL) 
adverse events in high-risk patients with T2D. This effect was consistent regardless of the 
patients' prior history of AF, ASCVD, or HF[51]. 
 
Observational data of cardiovascular effects of SGLT2 inhibitors  
Several observational, population-based, retrospective cohort studies have examined the 
effects of SGLT2 inhibitors on rates of death and/or hospitalisation for HF in patients with 
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T2D [52, 53]. In the THIN database from the UK, patients with T2D who were exposed to 
dapagliflozin had a lower risk of death from any cause (i.e. a lower all-cause mortality) 
irrespective of baseline CVD status [53]. Similarly, in the CVD-REAL study, data was 
collected from medical claims, primary care/hospital records and national registries from the 
US, Norway, Denmark, Sweden, Germany and the UK. Treatment with any SGLT2 inhibitor 
(canagliflozin, dapagliflozin and empagliflozin) versus other oral glucose-lowering drug 
treatments was associated with lower rates of hospitalisation for HF and death [52]. These 
findings have now been replicated in a further study from the Nordic registers [54]. A 
subsequent study, the CVD REAL 2 study, found that use of SGLT2 inhibitors (versus other 
glucose lowering drugs) in patients with T2D from Asia, Middle East and North America was 
associated with a lower risk of all cause death, hospitalisation for HF, MI and stroke[55].   
 
Potential mechanisms of cardiovascular benefit of SGLT2 inhibitors 
The mechanism by SGLT2 inhibitors mediates this reduction in CV death and HF remains 
unknown, although many theories have been proposed[56]. The findings, both in their nature 
and speed of onset, clearly implicate non-glycaemic mechanisms of benefit. Although T2D is 
a major risk factor for CVD, there is no evidence from this study, or indeed from any CV 
outcome study that the glucose lowering action mediates the beneficial effect in reducing 
CVD, HF or deaths. This is particularly reinforced by the findings of DAPA-HF where 
similar benefits were observed in those with or without T2D. For similar reasons the effects 
do not appear to be mediated by anti-atherogenic effects. Proposed cardiac mechanisms 
include cardiac remodelling, improved contractility and a shift in myocardial and renal 
substrate utilisation from fat and glucose oxidation toward an energy-efficient ‘super fuel’ 
like ketone bodies, which improve myocardial/renal work efficiency and function [57, 58]. 
Preservation of renal function may also help but a diuretic or natriuretic effect appears 
unlikely as intensification of diuretic therapy in HF is associated with an increased risk of CV 
and sudden death and in DAPA-HF, dapagliflozin, only produced a 10-15% decline in NT-
proBNP levels. Sustained volume contraction, by reducing myocardial stretch, may attenuate 
susceptibility to arrhythmias. 
The collective CV data and clinical trials context are summarised in Figures 3 and 4. 
 
D. Effects of SGLT2 inhibitors on chronic kidney disease 
CKD, as defined by the presence of kidney damage or glomerular filtration rate (GFR<60 
ml/min per 1.73 m
2
) for 3 months, is classified into stages based on the level of GFR [59]. 
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CKD affects 700 million individuals worldwide and contributes to 1 in 20 deaths annually 
[60]. As well as HF, T2D is frequently complicated by CKD (~40% of people with T2D) and 
T2D is now the leading cause of end-stage kidney disease (ESKD) globally. Indeed, these 
three entities (T2D, HF and CKD) are interconnected frequently co-existing such that 50% of 
individuals with HF have moderate-severe CKD. The co-existence of CKD and HF reflects 
many common aetiologies including advancing age, hypertension, coronary artery disease, 
and T2D [61]. The presence of any one of these conditions worsens the other two conditions 
[62]; hospitalisations due to HF are associated with a >11-fold increased risk of end-stage 
renal disease compared with patients who did not have CVD [63]. Furthermore, the presence 
of CKD in HF is associated with increased morbidity and mortality with a higher risk of all 
cause death, CV death and hospitalisation for HF [64]. Significantly, the risk of death in HF 
is more strongly associated with decline in eGFR than in ejection fraction [65]. 
In recent decades despite attempts to achieve optimal glycaemic and blood pressure control, 
and widespread use of ACEs/ARBs, there remains a high residual risk for patients with CKD 
to progress to end stage kidney disease (ESKD) which highlights the need for additional 
renoprotective therapies to preserve eGFR and prevent ESKD. The renoprotective effects of 
SGLT2 inhibitors were first demonstrated in EMPA-REG, DECLARE and CANVAS [35, 
37, 66] although all renal outcomes reported were secondary outcome measures. In a meta-
analysis of these three CVOTs, SGLT2 inhibitors reduced the composite of worsening renal 
function, end-stage renal disease or renal death by 45% (HR 0.55; 95% CI 0.48,0.64) with a 
similar effect whether studied in patients with atherosclerotic CVD or those with multiple 
risk factors [39] (Figure 5). Renoprotection was evident across all baseline GFR levels but 
with a progressively attenuated effect as eGFR declined. Importantly, these studies enrolled 
only a small fraction of patients with CKD at baseline (the lowest mean baseline eGFR was 
74 ml/min/1.73 m
2
 in EMPA-REG, 76.5 ml/min/1.73 m
2
 in CANVAS and 85 ml/min/1.73 m
2 
in DECLARE). Furthermore, fewer than 1/6 of participants has eGFR<60 ml/min/1.73 m
2 
with only a small proportion with baseline eGFR <45 ml/min/1.73 m
2
. Recognising the need 
to study the participants with the highest risk of adverse renal outcomes (i.e. those with the 
lowest eGFR), and thus the group who would derive the most benefit, studies of SGLT2 
inhibitors have been conducted or are underway. Currently, SGLT2 inhibitors are not 
approved for use in patients with eGFR<45 ml/min/1.73 m
2 
based on the diminished 
glycaemic efficacy with impaired renal function.  
The only currently published RCT designed to evaluate the renoprotective effects of an 
SGLT2 inhibitor in 4,401 people with T2D, CKD and macroalbuminuria, compared with a 
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placebo, is the CREDENCE study (Evaluation of the Effects of Canagliflozin on Renal and 
Cardiovascular Outcomes in participants with Diabetic Nephropathy) [67]. This study was 
designed specifically to examine the effects of SGLT2 inhibition on renal outcomes in 
patients with T2D at high risk of renal disease progression. Inclusion criteria was eGFR>30 
and <90 ml/min/1.73 m
2
 with UACR >300-5000mg/g with all patients receiving renin-
angiotensin system blockade with stable doses of ACEs/ARBs. Mean eGFR was 56.2 
ml/min/1.73 m
2
 with 60% had an eGFR of 30-60 ml/min/1.73 m
2
. The primary outcome 
measure was a composite of ESKD (dialysis, transplantation or a sustained eGFR of <15 
ml/min/1.73 m
2
), a doubling of serum creatinine or death from renal or cardiovascular causes. 
Secondary outcomes included cardiovascular outcomes. This study was terminated early after 
reaching the pre-specified efficacy criteria. The relative risk of the primary outcome was 
reduced by 30% in the canagliflozin group relative to placebo with a 20-30% lower relative 
risk of deleterious cardiovascular outcomes. It also provided reassurance about the risk of 
amputation/fracture with similar rates between the two groups. This study demonstrated 
benefit for patients of all eGFR groups including those with a low baseline eGFR (eGFR 30-
45 ml/min/1.73 m
2
 in whom SGLT2 inhibitors would not currently be recommended).  
A further systematic review and meta-analysis which pooled data from the 3 CVOTs and 
CREDENCE, including a total of 38,723 participants, demonstrated consistent reductions in 
all the major kidney outcomes including acute kidney injury [68] (Figure 5). Significantly, 
there was clear separate evidence of benefit across all groups, irrespective of baseline eGFR, 
albuminuria or use of RAS blockade. The evidence from CREDENCE and this meta-analysis 
highlight a renoprotective role for patients with T2D and eGFR of 30-45 ml/min/1.73 m
2
. 
 
Studies of SGLT2 inhibition and CKD without T2D 
The results of the DAPA-CKD trial have extended these findings to the broader population of 
patients with CKD (including participants with an eGFR 25-75 ml/min/1.73 m
2
), consisting 
approximately two thirds of the population
 
with and one third without T2D, and demonstrated 
that the SGLT2 inhibitor, dapagliflozin, conferred kidney protection in patients with CKD. 
The occurrence of the composite primary outcome measure of a sustained decline in eGFR of 
at least 50%, end-stage kidney disease or death from renal/cardiovascular causes was reduced 
by 44%. Similarly, the risk of a composite of death from cardiovascular causes or 
hopsitalisation for heart failure was reduced by 29%.[69]. 
A short-term (6 week) randomised double-blind, placebo-controlled, cross-over study (the 
DIAMOND study) has examined the effects of dapagliflozin on proteinuria in non-diabetic 
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patients with CKD and on stable RAS blockade. Although this did not show a difference in 
mean proteinuria change from baseline between dapagliflozin and placebo, this may reflect 
the short study duration and the outcomes of longer-term clinical trials are awaited [70].  
 
Current renal outcome studies  
EMPA-KIDNEY evaluating empagliflozin in patients with CKD, with or without T2D, is 
currently underway. Results from this study, with the results from DAPA-CKD, will likely 
pave the way for their application in patients with CKD, irrespective of a background of T2D.  
 
Observational studies 
In clinical practice there is a more heterogenous population of patients that receive SGLT2 
inhibitors than those randomised in placebo controlled clinical trials and thus real-life studies 
assess whether clinical trial data extends to patients treated in routine clinical practice. CVD-
REAL 3 was a multi-national, observational cohort study examining new users of SGLT2 
inhibitors with other glucose lowering drugs with measurements of eGFR before and 180 
days after initiation [71]. During follow up, SGLT2 inhibitor initiation was associated with 
reduced eGFR decline and a lower risk of major kidney events compared with initiation of 
other glucose-lowering drugs.  
In another such study, using nationwide data from routine clinical practice in Scandinavia 
(Sweden, Denmark and Norway) Pasternak et al., demonstrated that initiation of SGLT2 
inhibitors, compared with dipeptidyl peptidase-4 inhibitors using propensity matching, was 
associated with a significantly reduced risk of renal events reflecting a composite including 
renal replacement therapy, death from renal causes and hospital admission for renal events 
(3.6 fewer events per 1,000 patient years; hazard ratio 0.42, 95% CI 0.34, 0.53) [72]. These 
results suggest results in routine clinical practice are broadly similar to those observed in 
clinical trials.  
 
Potential mechanisms of renal benefits of SGLT2 inhibitors 
Our understanding of the underlying mechanisms through which SGLT2 inhibitors achieve 
renal protection is evolving [73]. Good glycaemic control is critical to preventing diabetic 
kidney disease and so metabolic effects with glucose lowering, improved insulin sensitivity, 
and lesser glucose toxicity all contribute beneficially but there are multiple important non-
glycaemic mechanisms of action. Some of these reflect direct effects of SGLT2 inhibition on 
the kidney mediated by the natriuretic effects including normalisation of glomerular 
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haemodynamics through restoration of tubuloglomerular feedback (TGF), anti-inflammatory 
and anti-fibrotic actions and improving renal energy efficiency. Others relate to indirect 
effects including reductions in blood pressure and in body weight.  
The collective renal data and clinical trials context is summarised in Figures 5 and 6. 
 
E. Placement of SGLT2 inhibitors in the T2D treatment pathway  
Recently, a consensus report by the American Diabetes Association (ADA) and the European 
Association for the Study of Diabetes (EASD) provided updated recommendations on the 
management of hyperglycaemia [74]. Incorporating the recently amassed clinical trial 
evidence-base of SGLT2 inhibitors on CV and renal outcomes, the treatment algorithm 
proposes an initial distinction of glucose-lowering medication based on clinical 
characteristics and the presence or absence of co-morbidities such as atherosclerotic CVD, 
HF or CKD. For patients with clinical CVD, an SGLT2 inhibitor or a GLP-1 receptor agonist 
with proven cardiovascular benefit is recommended while for those patients with CKD or HF 
and atherosclerotic cardiovascular disease, an SGLT2 inhibitor with proven benefit is 
recommended. They also recommend consideration of an SGLT2 inhibitor or GLP1-RA 
where there is a compelling need to minimise weight gain or promote weight loss or to 
minimise hypoglycaemia. This stratification of high-risk individuals to receive SGLT2 
inhibitors (or GLP1-RA) is an important departure from previous guidelines.  
 
F. Development of dual SGLT inhibition 
Given the increased transport capacity of SGLT1 for glucose following SGLT2 inhibition, 
and the significant role of SGLT1 in intestinal glucose uptake, optimising dual SGLT 
inhibition is an appealing strategy. As well as being identified in the human kidney and 
intestine, SGLT1 is expressed in the liver, heart, skeletal muscle, lung, and possibly brain, 
indicative of several extra-renal functions of this transporter [75]. Mechanistic studies are 
needed to determine the functional role of SGLT1 at these locations. 
The therapeutic potential of phlorizin was limited, due to poor oral availability, and effects on 
gut glucose absorption that resulted in diarrhoea. Sotagliflozin is the first dual SGLT 
inhibitor licensed for the treatment of T1D, in combination with insulin, in Europe. 
Compared to selective SGLT2 inhibitors, sotagliflozin has similar efficacy in terms of 
glycaemic control and weight loss and despite its increased selectivity for SGLT1 is well 
tolerated without severe gastrointestinal side effects, most likely due to incomplete SGLT1 
inhibition [76]. 
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In a small, proof of concept, randomised controlled trial, lucagliflozin, a selective and potent 
dual SGLT1/SGLT2 inhibitor, demonstrated significant weight loss (5.7% vs placebo (P < 
0.001) in patients with obesity, and favourable increases in incretin hormones and urinary 
glucose excretion (~100g) in patients with T2D [77]. A higher incidence of diarrhoea was 
reported at higher doses of lucagliflozin, possibly explained by greater SGLT1 inhibition. 
Evaluation of the long-term efficacy and safety of existing or developing SGLT1 and dual 
SGLT inhibitors is required, in particular risk of diabetic ketoacidosis and cardiovascular 
outcomes. 
 
G. Combination therapy 
GLP-1 receptor agonist The glucose lowering effects of SGLT2 inhibitors are attenuated due 
to increased endogenous (hepatic) glucose production, partially explained by 
hyperglucagonaemia. Combined with the concept of compensatory hyperphagia with SGLT2 
inhibitor therapy, a clear rationale for the co-administration of an SGLT2 inhibitor with a 
GLP-1 receptor agonist is provided. The aim of combination treatment would be to offset the 
compensatory metabolic changes and attenuate the central hyperphagic drive and ideally 
achieve additive, even synergistic, weight loss and metabolic changes. Two clinical trials 
have examined the glucose lowering efficacy and weight change when a SGTL2 inhibitor is 
combined with a GLP-1 receptor agonist in T2D [78, 79]. Mechanistic explanations for 
weight loss associated with SGLT2 inhibitors, with or without GLP1 receptor agonists have 
been discussed narratively [28].   
Combination of SGLT2 and GLP-1 receptor agonist on CVD In the EXSCEL study, open-
label SGLT2 inhibitor use, in parallel with, or shortly after once weekly exenatide, occurred 
in 8.7% of participants.  Those on combination therapy were propensity-matched to those on 
placebo only and those on once weekly exenatide only. The risk for MACE and  all-cause 
mortality was numerically lower, and the estimated eGFR slope improved,  with combination 
therapy compared with placebo or once weekly exenatide only alone supporting the 
hypothesis that combinatorial therapy may provide benefit on cardiovascular outcomes and 
mortality [80].  
DPP-4 inhibitor DPP-4 inhibitors are less potent than GLP-1 receptor agonists with an 
average HbA1c reduction of -0.74% [81] and they are considered to be weight neutral. Very 
small mechanistic studies with dual SGLT1/2 inhibitors have demonstrated increased 
circulating levels of GLP-1, presumably due to delayed SGLT1-mediated intestinal glucose 
absorption [77, 82]. Developed to inhibit the degradation of endogenous GLP-1 and other 
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glucoregulatory peptides, the glycaemic improvement seen with combination of a SGLT2 
inhibitor with a DPP-4 inhibitor is modest and sub-additive [83]. Although clinically relevant 
improvements in HbA1c are seen, it seems that DPP4-inhibitors are unable to offset the 
(mal)adaptive changes in hepatic glucose production and hyperglucagonaemia seen with 
SGTL2 inhibitors. 
Combination of SGLT2 and DPP4-inhibitor on kidney disease The DELIGHT study 
examined  
the albuminuria-lowering effect of dapagliflozin, with and without saxagliptin, in patients 
with T2D and moderate-to-severe CKD [84]. Dapagliflozin alone or in combination with 
saxagliptin, versus placebo, reduced the urinary albumin-creatinine ratio (by 21 and 38% 
respectively). 
 
H. Adverse effects  
Data is continually emerging around the adverse effects and risks associated with SGLT2 
inhibitors from a variety of sources including extensive clinical experience, case series, post-
marketing surveillance and regulatory websites [85]. The most common adverse effect is 
genital mycotic infections although there also be a slightly increased risk of urinary tract 
infections and there have been concerns about Fournier’s gangrene, a necrotizing fasciitis of 
the scrotum [86]. Other signals include diabetic ketoacidosis, foot and leg amputation and 
bone fracture briefly discussed below.  
 
Diabetic ketoacidosis (DKA) (Figure 7) 
DKA, the triad of hyperglycaemia (blood glucose >11 mmol/l), acidosis (venous bicarbonate 
<15 mmol/l) and ketonuria/ketonaemia, represents the most common and serious 
hyperglycaemic emergency in patients with diabetes. Most commonly it occurs in auto-
immune T1D but can also occur in poorly controlled, insulin-deficient patients with T2D 
[87].  In 2015, regulatory authorities (the Federal Drug Administration and the European 
Medicines Agency) first advised clinicians that the use of SGLT2 inhibitors was associated 
with an increased risk of diabetic ketoacidosis (DKA). In one analysis from the US FDA 
Adverse Event Reporting Systems (FAERS), 71% presented with normal or only mildly 
elevated plasma glucose concentrations, euglycaemic ketoacidosis (EuDKA) [88], with 
relative normoglycaemia presumably maintained by augmented renal glycosuria. This is an 
important practical issue as the minimal hyperglycaemia may result in a delay in the 
diagnosis in >50% of individuals with lesser degrees of dehydration given the lack of 
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hyperglycaemia. A further analysis from FAERS subsequently reported >2500 cases of DKA 
in which SGLT2 inhibitors were listed as suspect or concomitant drugs [89]. Case series have 
helped identify common themes, and in particular precipitating events including intercurrent 
illness e.g. vomiting/diarrhoea, dehydration, discontinuation or reduction of insulin dosage 
related to glycaemic improvement, surgery, fasting or ketogenic/low carbohydrate diet and 
excessive  alcohol [90]. A recent meta-analysis of 39 RCTs, involving >60,000 patients with 
T2D, confirmed SGLT2 inhibitors were statistically associated with an increased risk of 
DKA versus control (odds ratio 2.13, 95% CI 1.38, 3.27) [91]. However, it is generally 
considered to be a rare event. In contrast, DKA, in the context of T1D is more common, with 
or without the use of SGLT2 inhibitors, but off-label use of SGLT2 inhibitors, especially 
among young females was a risk factor [92].The rates of DKA and ketosis with SGLT2 
inhibitors in T1D may be between 5-10% based on clinical trial data in T1D [93]. 
There are multiple biologically plausible mechanisms by which SGLT2 inhibitors cause 
ketosis or DKA in T1D or T2D (illustrated in Figure 7). The lowering of plasma glucose will 
lead to lower insulin levels, coupled with an increased glucagon secretion associated with 
SGLT2 inhibitors, with a consequently increased glucagon: insulin ratio. This raised 
glucagon: insulin concentration drives lipolysis, fatty acid oxidation and ketone production 
by the liver. Simultaneously, increased ketone body reabsorption may occur through the 
kidney secondary to renal glucose loss. All of this may be compounded by a reduction in 
insulin dosage or even a discontinuation of insulin in patients with T1D, or in patients with 
T2D who are insulin deficient.  
Patients with T2D and particularly those with T1D being initiated on SGLT2 inhibitors need 
to be carefully counselled about this potential risk, the associated symptoms and educated 
about ketone monitoring. Recently international consensus guidelines have been compiled to 
mitigate the risk the associated DKA risk in patients with T1D being treated with SGLT2 
inhibitors [94]. Any patient with T1D or T2D who experience nausea, vomiting, is generally 
unwell or develops a metabolic acidosis in the setting of SGLT2 inhibitor therapy, should 
undergo prompt evaluation of ketonuria/ketonaemia.  
 
Lower limb amputation  
In CANVAS there was an increased risk of lower limb amputation observed with 
canagliflozin, primarily at the level of the toe or metatarsal, although this has not been 
reproduced in other studies with other SGLT2 inhibitors, nor was any concern noted 
regarding canagliflozin use in CREDENCE[66, 67]. It is unclear to what extent canagliflozin 
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increases the amputation risk, if at all, but caution is advised in patients with risk factors for 
lower limb amputation. Risk factors for amputation with SGLT2 inhibitors include those with 
a previous history of amputation or foot ulcers, peripheral vascular disease and neuropathy 
and those with baseline CVD.  
 
Bone health 
The association between SGLT2 inhibitors and risk of fractures is based on findings from 
CANVAS, which found a significant increased risk of fractures compared with placebo 
(hazard ratio, 1.26; 95% CI 1.04,1.52)[66]. Biologically plausible mechanisms would 
underlie this including elevated serum phosphate levels or reduced bone mineral density. 
These findings were not reproduced in CREDENCE where there was a similar fracture risk in 
both groups[67]. In a subsequent population-based cohort study in the UK, the use of SGLT2 
inhibitors was not associated with an increased risk of fractures compared with use of DPP-4 
inhibitors[95].  
 
I. Summary  
SGLT2 inhibitors have become an indispensable part of the therapeutic armamentarium in 
T2D with useful metabolic effects in all patients with little or no risk of hypoglycaemia. 
Their role in T1D is emerging with a need for careful patient selection and a need for ongoing 
pharmacovigilance. In T2D, they have a very clear role emerging in high-risk patients with 
atherosclerotic CVD, HF and CKD and their use is expanding to other patient groups who do 
not have diabetes, particularly those with HF of chronic kidney disease. Results of further 
ongoing randomised controlled trials will, no doubt, expand the clinical indications for these 
drugs in diverse patient populations and we can continue on this exciting journey of 
discovery. 
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Figure legends  
Figure 1 Renal glucose handling  
Figure 2 Glucose transport mechanisms in segments S1 and S2 of the renal tubules and in the 
enterocyte of the small intestine  
Figure 3 A) Effect on MACE stratified by the presence of established atherosclerotic CVD 
or multiple risk factors, B) Effect on hospitalisation for HF and CV death stratified according 
to history of atherosclerotic CVD or multiple risk factors, C) Effect on hospitalisation for HF 
and CV death stratified according to history of HF [39] 
Figure 4 Summary of the main cardiovascular outcome trials  
Figure 5 Summary of the effects of the SGLT2 inhibitors on the major kidney outcomes A) 
and B) from EMPA-REG, CANVAS and DECLARE, C) also incorporating CREDENCE 
data [39, 68] 
Figure 6 Summary of the main studies with SGLT2 inhibitors and renal outcomes 
Figure 7 Mechanisms of diabetic ketoacidosis with SGLT2 inhibitors  
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Referenc
es 
Population 
Intervention 
(Drug/duratio
n) 
Comparat
or 
Outcome  
(Baseline/20 weeks for drug vs 
control) 
    ALT Liver fat 
(%) 
Liver 
fibrosis 
(FIB-4) 
Johansson 
et al 
(2020) 
(82) 
Type 2 diabetes Metformin + 
Dapagliflozin 
10mg od + 
Saxagliptin 
5mg od (D+S) 
(n=35) 
Metformin 
+ 
Glimepirid
e (G) (1-
6mg) od 
(n=24) 
Δ ALT -5.3 
(D+S) 
vs  
2.1) (G)  
Baseline 
14.3 (6.4) 
(D+S) 
13.7 (8.3) 
(G)  
Week 52 
9.9 (7.1) 
(D+S)  
12.9 (8.6) 
(G) 
(MRI-
PDFF) 
(D+S vs G, 
p<0.05) 
Not 
measure
d 
Sattar et 
al (2018) 
(58) 
EMPA-REG 
Outcome ® trial  
Empagliflozin 
10/25mg 
(n=4,611) 
164 weeks 
Placebo (P) 
(n=2,313) 
Δ ALT -
2.96 (E) vs - 
0.73 (P) 
(E vs P, 
p<0.05) 
Not 
measured 
Not 
measure
d 
Eriksson 
et al 
(2018) 
(60) 
Type 2 diabetes 
+ NAFLD 
Dapagliflozin 
10mg (n=21), 
Dapagliflozin 
+ OM3-CA 
(DO) (n=22) 
12 weeks 
Placebo (P) 
(n=21) 
67/53 (D) vs 
57/54 (P) (D 
vs P, 
p<0.05) 
17.3/15.1 
(D) vs 
22.2/19.1 
(DO) vs 
15.1/14.5 
(P) 
(MRI-
PDFF) 
(D vs P, 
p=ns, DO 
vs P, 
p<0.05) 
Not 
measure
d 
Shibuya 
et al 
(2018) 
(83) 
Type 2 diabetes 
+ NAFLD 
Luseogliflozin 
2.5 mg (L) 
(n=16) 
26 weeks 
Metformin 
1500 mg 
(M) (n=16) 
49.5/31 
(p=ns) (L) 
vs 39/39 
(p=ns) (M) 
(L vs M, 
p=ns)  
0.9097/1.0
33 
(p=0.0008) 
(L) 
0.991/0.85
1 (p=0.017) 
(M) 
(CT 
liver/spleen 
ratio) 
(L vs M, 
p<0.05)  
Not 
measure
d 
Kuchay et 
al (2018) 
(59) 
Type 2 diabetes 
+ NAFLD  
Empagliflozin 
(E) 10 mg od 
(n=22) 
20 weeks 
Control 
(standard 
type 2 
diabetes 
64(20)/50(2
6) (p<0.05) 
(E) vs 
65(40)/62(3
16.2/11.3 
(E) 
(p<0.05) vs 
16.4/15.5 
Not 
measure
d 
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treatment) 
(C) (n=20) 
8) (p=ns) 
(C) 
(E vs C, 
p<0.05) 
% (p=ns) 
(C) 
(MRI-
PDFF) 
(E vs C, 
p<0.05) 
Cusi et al 
(2018) 
(84) 
Type 2 
diabetes(HbA1c
 = 7.7% ± 
0.7%) 
Canagliflozin 
(Cf) 300mg 
(n=26) 
24 weeks 
Placebo (P) 
(n=30) 
23/20 (Cf) 
vs 35/34 (P) 
(Cf vs P, 
p=ns) 
IHTG: -
4.6% (Cf) 
(p<0.05) vs 
-2.4% (P) 
(p<0.05)  
(
1
H-MRS) 
(Cf vs P, 
p=ns) 
IHTG for 
NAFLD 
patients 
only 
(n=37): -
6.9% (Cf) 
vs -3.8% 
(P) 
 (Cf vs P, 
p=0.05) 
Not 
measure
d 
Ito et al 
(2017) 
(85) 
Type 2 diabetes 
+ NAFLD 
Ipragliflozin 
(I) 50mg 
(n=30) 
24 weeks 
Pioglitazon
e (P) 15-
30mg 
(n=31) 
57.4/38.2 
(p<0.05) (I) 
v. 53.1/46.8 
(p<0.05) (P)  
 (I vs P, 
p=ns) 
0.78/0.98 
(p<0.05) (I) 
0.72/0.94 
(p<0.05) 
(P) 
(CT 
liver/spleen 
ratio) 
(I vs P, 
p=ns) 
2.12/1.6
1 
(p<0.05
) (I)  
2.06/1.7
0 
(p<0.05
) (P) 
 (I vs P, 
p=ns) 
Bolinder 
et al 
(2012) 
(15) 
Type 2 diabetes 
 
Dapagliflozin 
(D) 10 mg od 
+ metformin 
(n=89) 
24 weeks 
Placebo (P) 
+ 
metformin 
(n=91)  
Not 
reported in 
sub-study 
Change in 
intrahepatic 
lipid was -
2.35% (D) 
vs -1.53% 
(P) (
1
H-
MRS) 
(D vs P, 
p=ns) 
Not 
measure
d 
 
ALT, alanine aminotransferase; FIB-4; fibrosis-4 score; NAFLD, non-alcoholic fatty liver disease; 
OM3-CA, omega-3 carboxylic acids; MRI-PDFF, magnetic resonance imaging proton density fat 
fraction; 
1
H-MRS, proton magnetic resonance spectroscopy; CT, computed tomography; IHTG 
intrahepatic triglyceride  
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